Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) traded down 13.9% on Monday . The company traded as low as C$0.15 and last traded at C$0.16. 16,459,333 shares were traded during trading, an increase of 1,795% from the average session volume of 868,420 shares. The stock had previously closed at C$0.18.
Hemostemix Stock Down 13.9 %
The firm has a 50-day simple moving average of C$0.21 and a 200 day simple moving average of C$0.12. The stock has a market capitalization of C$22.59 million, a P/E ratio of -4.52 and a beta of 0.20. The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- Financial Services Stocks Investing
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- When to Sell a Stock for Profit or Loss
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- Short Selling: How to Short a Stock
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
